Drugs / RPH-035
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07597668 | Apr 2025 → Jun 2026 overdue | multiple sclerosis | R-Pharm | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPH-035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07597668 ↗ |
| Route | Intravenous | “During the After-Therapy Period, patients will receive an IV infusion of ocrelizumab (RPH-035) at a dose of 600 mg” NCT07597668 ↗ |